-
Kenya's economy faces climate change risks: World Bank
-
Vietnam and EU upgrade ties as EU chief visits Hanoi
-
Hongkongers snap up silver as gold becomes 'too expensive'
-
Gold soars past $5,500 as Trump sabre rattles over Iran
-
Samsung logs best-ever profit on AI chip demand
-
China's ambassador warns Australia on buyback of key port
-
As US tensions churn, new generation of protest singers meet the moment
-
Venezuelans eye economic revival with hoped-for oil resurgence
-
Samsung Electronics posts record profit on AI demand
-
French Senate adopts bill to return colonial-era art
-
Tesla profits tumble on lower EV sales, AI spending surge
-
Meta shares jump on strong earnings report
-
Anti-immigration protesters force climbdown in Sundance documentary
-
Springsteen releases fiery ode to Minneapolis shooting victims
-
SpaceX eyes IPO timed to planet alignment and Musk birthday: report
-
Neil Young gifts music to Greenland residents for stress relief
-
Fear in Sicilian town as vast landslide risks widening
-
King Charles III warns world 'going backwards' in climate fight
-
Court orders Dutch to protect Caribbean island from climate change
-
Rules-based trade with US is 'over': Canada central bank head
-
Holocaust survivor urges German MPs to tackle resurgent antisemitism
-
'Extraordinary' trove of ancient species found in China quarry
-
Google unveils AI tool probing mysteries of human genome
-
UK proposes to let websites refuse Google AI search
-
Trump says 'time running out' as Iran threatens tough response
-
Germany cuts growth forecast as recovery slower than hoped
-
Amazon to cut 16,000 jobs worldwide
-
Greenland dispute is 'wake-up call' for Europe: Macron
-
Dollar halts descent, gold keeps climbing before Fed update
-
Sweden plans to ban mobile phones in schools
-
Deutsche Bank offices searched in money laundering probe
-
Susan Sarandon to be honoured at Spain's top film awards
-
Trump says 'time running out' as Iran rejects talks amid 'threats'
-
Spain eyes full service on train tragedy line in 10 days
-
Greenland dispute 'strategic wake-up call for all of Europe,' says Macron
-
SKorean chip giant SK hynix posts record operating profit for 2025
-
Greenland's elite dogsled unit patrols desolate, icy Arctic
-
Uganda's Quidditch players with global dreams
-
'Hard to survive': Kyiv's elderly shiver after Russian attacks on power and heat
-
Polish migrants return home to a changed country
-
Dutch tech giant ASML posts bumper profits, eyes bright AI future
-
Minnesota congresswoman unbowed after attacked with liquid
-
Backlash as Australia kills dingoes after backpacker death
-
Omar attacked in Minneapolis after Trump vows to 'de-escalate'
-
Dollar struggles to recover from losses after Trump comments
-
Greenland blues to Delhi red carpet: EU finds solace in India
-
French ex-senator found guilty of drugging lawmaker
-
US Fed set to pause rate cuts as it defies Trump pressure
-
Trump says will 'de-escalate' in Minneapolis after shooting backlash
-
CERN chief upbeat on funding for new particle collider
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.K.Baumgartner--CPN